Royalty Pharma to acquire royalty interest in Geron’s RYTELO for $125M

Royalty Pharma (RPRX) announced that it will acquire a synthetic royalty on U.S. sales of Geron Corporation’s (GERN) RYTELO for $125 million in cash upfront. “RYTELO is an important therapy for the lower-risk MDS patient population, who otherwise have limited treatment options, and we look forward to its development in other hematologic malignancy indications. We are delighted to establish this partnership with Geron to help fuel their execution of significant commercial and development opportunities ahead” said Pablo Legorreta, founder and Chief Executive Officer of Royalty Pharma.